# CatalYm GmbH

> CatalYm is a German clinical-stage biotech developing visugromab, a GDF-15 neutralizing monoclonal antibody designed to reverse immunotherapy resistance in solid tumors and address cancer cachexia.

- **Founded:** 2016
- **Headquarters:** Planegg, Germany
- **Founders:** Joerg Wischhusen (Scientific Founder), Eugen Leo (Co-Founder, former CMO), Christine Schuberth-Wagner (Co-Founder), Manfred Ruediger (Co-Founder, former CEO)
- **Team size:** approx. 58
- **Products:** Visugromab (CTL-002)
- **Notable:** Phase 1/2a clinical proof-of-concept for reversing checkpoint inhibitor resistance via GDF-15 neutralization, published in Nature (2024)., Raised $150M Series D in July 2024 to fund global Phase 2b program., Positive follow-up Phase 2a data presented at ASCO 2024 in NSCLC, urothelial and hepatocellular cancer.

## Products & services

- **Visugromab (CTL-002)** — A clinical-stage humanized monoclonal antibody that neutralizes GDF-15, a tumor-derived cytokine that drives resistance to checkpoint inhibitors and contributes to cancer cachexia.

## Achievements

- Phase 1/2a clinical proof-of-concept for reversing checkpoint inhibitor resistance via GDF-15 neutralization, published in Nature (2024).
- Raised $150M Series D in July 2024 to fund global Phase 2b program.
- Positive follow-up Phase 2a data presented at ASCO 2024 in NSCLC, urothelial and hepatocellular cancer.
- New AACR 2025 data showing GDF-15 blockade enhances antibody-drug conjugate efficacy.

## Latest updates

- **2025-04** — Presented data at AACR 2025 showing GDF-15 blockade improves ADC efficacy.
- **2024-07** — Closed $150M Series D financing.
- **2024-06** — Phase 2a follow-up data presented at ASCO 2024.
- **2024** — Visugromab Phase 1/2a results published in Nature.

## Links

- Website: https://catalym.com
- LinkedIn: https://www.linkedin.com/company/catalym

---

Profile page: https://yespress.io/catalym-gmbh
Published by YesPress — https://yespress.io
Last updated: 2026-05-19